Company profile: Glycotope
1.1 - Company Overview
Company description
- Provider of GMP-compliant contract manufacturing for active biopharmaceutical ingredients (proteins and antibodies) via recombinant production, and oncology antibody solutions including GT-001 (Lewis Y), GT-002 (LYPD3), GT-00A (MUC1) and an IL-15 immuno-cytokine, plus GlycoTarget Discovery and a platform enabling high tumor-specificity by targeting tumor-associated carbohydrates for ADC/CAR development.
Products and services
- Proprietary Technology Platform: Custom-engineered system enabling development of antibodies with high tumor-specificity by targeting tumor-associated carbohydrate structures, enhancing selective binding for cancer-directed antibody products
- GlycoTarget Discovery: Industrial-grade, multi-parameter approach identifying proteins with cancer-specific glycopeptide epitopes for antibody development, supplying robust target selection to architect highly tumor-specific therapeutic antibodies
- GT-00A based IL-15 immuno-cytokine: Bioengineered construct derived from GT-00A, designed to activate immune cells at the tumor site for localized antitumor activity through IL-15 engagement
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Glycotope
Reata Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies for cancer, inflammation, neurodegenerative, renal, cardiovascular, and autoimmune diseases, including antioxidant and inflammation-modulating drugs and agents that correct protein misfolding. Offers Skyclarys (omaveloxolone), an FDA-approved treatment for Friedreich's Ataxia in patients 16+.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Reata Pharmaceuticals company profile →
NovaTarg
HQ: United States
Website
- Description: Provider of tissue-targeted medicine discovery and cancer treatment programs. NovaTarg Therapeutics is a privately owned pharmaceutical company with a leadership team experienced in drug discovery and a novel approach to the discovery of tissue-targeted medicines; offerings include NT1195, a treatment program aimed at addressing cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NovaTarg company profile →
AbbVie
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies and precision medicine across immunology, oncology, neuroscience, virology, and aesthetics. Offers HUMIRA for autoimmune conditions, IMBRUVICA for certain cancers, and RINVOQ for inflammatory diseases. Delivers genomics research and the AbbVie R&D Convergence Hub (ARCH) to integrate data and advance personalized drug discovery and treatment insights.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AbbVie company profile →
Adnexus Therapeutics
HQ: United States
Website
- Description: Provider of discovery and development of Adnectins, a novel proprietary class of targeted biologics designed to block or stimulate therapeutic targets to fight diseases across a broad range of therapeutic areas; operates as a Bristol-Myers Squibb R&D company in the United States.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adnexus Therapeutics company profile →
Retrophin
HQ: United States
Website
- Description: Provider of therapies and programs for rare diseases, including FILSPARI (sparsentan) for adults with IgA nephropathy; a late-stage therapy for focal segmental glomerulosclerosis; a potential disease-modifying therapy for classical homocystinuria; preclinical Alagille syndrome research with NIH and ALGSA; and support for newborn screening modernization and a telehealth model to improve specialist access.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Retrophin company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Glycotope
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Glycotope
2.2 - Growth funds investing in similar companies to Glycotope
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Glycotope
4.2 - Public trading comparable groups for Glycotope
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →